Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Man who grabbed Ariana Grande at 'Wicked: For Good' premiere also rushed Katy Perry onstage this year. Who is he and why is he doing this? - 2Exploring Asia’s Realm of Flying Snakes
- 3Italy now recognizes the crime of femicide and punishes it with life in prison
- 4'Set up an Army Radio station at President’s Residence': Source close to Katz slams Herzog
- 5SpaceX rocket launches 140 satellites into orbit on Transporter-15, aces landing at sea (video)
- Select Your Cherished Fish
- New Year's superstitions: Eating 12 grapes, avoiding laundry and other rituals that are said to bring good fortune
- US students studying housing, health outcomes and sustainability win 2026 Rhodes scholarships
- Vote In favor of Your Favored Pizza Cover
- Little Urban areas to Visit in Western Europe
- King Charles III says he is reducing cancer treatment schedule in 2026
- Palestinians tell BBC they were sexually abused in Israeli prisons
- Figure out How to Explore the Infotainment Framework in the Slam 1500.
- Vote In favor of Your Favored Web based Dating Application
